Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Kent

Showing results (81-90 of 268) with videos related to

Pageof 27
Sort By:
Muscle & Nerve|April 14, 2021
The cumulative incidence of dysphagia and dysphagia-free survival in persons diagnosed with amyotrophic lateral sclerosisBridget J Perry, Jason Nelson, John B Wong, et al.
BJU International|May 15, 2014
Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH)Michael A Kozminski, John T Wei, Jason Nelson, et al.
Journal of Clinical Epidemiology|June 14, 2019
Models with interactions overestimated heterogeneity of treatment effects and were prone to treatment mistargetingDavid van Klaveren, Theodor A Balan, Ewout W Steyerberg, et al.
Stroke|October 28, 2006
The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic strokeDavid M Kent, Harry P Selker, Robin Ruthazer, et al.
Circulation. Cardiovascular Quality and Outcomes|January 16, 2014
Using internally developed risk models to assess heterogeneity in treatment effects in clinical trialsJames F Burke, Rodney A Hayward, Jason P Nelson, et al.
Structural Heart : the Journal of the Heart Team|September 9, 2020
Can Clinical Predictive Models Identify Patients Who Should Not Receive TAVR? A Systematic ReviewBenjamin S Wessler, Andrew R Weintraub, James E Udelson, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|August 31, 2017
Biases in Individualized Cost-effectiveness Analysis: Influence of Choices in Modeling Short-Term, Trial-Based, Mortality Risk Reduction and Post-Trial Life ExpectancyDavid van Klaveren, John B Wong, David M Kent, et al.
BMJ (Clinical Research Ed.)|November 6, 2015
Three simple rules to ensure reasonably credible subgroup analysesJames F Burke, Jeremy B Sussman, David M Kent, et al.
Journal of General Internal Medicine|May 17, 2018
Effects of Race Are Rarely Included in Clinical Prediction Models for Cardiovascular DiseaseJessica K Paulus, Benjamin S Wessler, Christine M Lundquist, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 25, 2003
Suitable monitoring approaches to antiretroviral therapy in resource-poor settings: setting the research agendaDavid M Kent, Donnie McGrath, John P A Ioannidis, et al.
Pageof 27

Showing results (81-90 of 268) with videos related to

Sort By:
Pageof 27
Muscle & Nerve|April 14, 2021
The cumulative incidence of dysphagia and dysphagia-free survival in persons diagnosed with amyotrophic lateral sclerosisBridget J Perry, Jason Nelson, John B Wong, et al.
BJU International|May 15, 2014
Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH)Michael A Kozminski, John T Wei, Jason Nelson, et al.
Journal of Clinical Epidemiology|June 14, 2019
Models with interactions overestimated heterogeneity of treatment effects and were prone to treatment mistargetingDavid van Klaveren, Theodor A Balan, Ewout W Steyerberg, et al.
Stroke|October 28, 2006
The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic strokeDavid M Kent, Harry P Selker, Robin Ruthazer, et al.
Circulation. Cardiovascular Quality and Outcomes|January 16, 2014
Using internally developed risk models to assess heterogeneity in treatment effects in clinical trialsJames F Burke, Rodney A Hayward, Jason P Nelson, et al.
Structural Heart : the Journal of the Heart Team|September 9, 2020
Can Clinical Predictive Models Identify Patients Who Should Not Receive TAVR? A Systematic ReviewBenjamin S Wessler, Andrew R Weintraub, James E Udelson, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|August 31, 2017
Biases in Individualized Cost-effectiveness Analysis: Influence of Choices in Modeling Short-Term, Trial-Based, Mortality Risk Reduction and Post-Trial Life ExpectancyDavid van Klaveren, John B Wong, David M Kent, et al.
BMJ (Clinical Research Ed.)|November 6, 2015
Three simple rules to ensure reasonably credible subgroup analysesJames F Burke, Jeremy B Sussman, David M Kent, et al.
Journal of General Internal Medicine|May 17, 2018
Effects of Race Are Rarely Included in Clinical Prediction Models for Cardiovascular DiseaseJessica K Paulus, Benjamin S Wessler, Christine M Lundquist, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 25, 2003
Suitable monitoring approaches to antiretroviral therapy in resource-poor settings: setting the research agendaDavid M Kent, Donnie McGrath, John P A Ioannidis, et al.
Pageof 27